N@N

Gil Blum Maintained (SRPT) at Strong Buy with Decreased Target to $160 on, Mar 17th, 2023

Gil Blum of Needham, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Decreased Target from $200 to $160 on, Mar 17th, 2023.

Gil has made no other calls on SRPT in the last 4 months.

There are 9 other peers that have a rating on SRPT. Out of the 9 peers that are also analyzing SRPT, 0 agree with Gil's Rating of Hold.

These are the ratings of the 9 analyists that currently disagree with Gil

---

• Hartaj Singh of "Oppenheimer" Maintained at Buy with Decreased Target to $150 on, Thursday, March 9th, 2023
• Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $206 on, Friday, March 3rd, 2023
• Brian Skorney of "Baird" Maintained at Buy with Increased Target to $202 on, Wednesday, March 1st, 2023
• Matthew Harrison of "Morgan Stanley" Upgraded from Hold to Buy and Increased Target to $187 on, Wednesday, March 1st, 2023
• Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $190 on, Wednesday, March 1st, 2023
• Gavin Clark-Gartner of "Evercore ISI Group" Maintained at Buy with Increased Target to $171 on, Wednesday, March 1st, 2023
• Joseph Schwartz of "SVB Leerink" Reiterated at Buy and Held Target at $160 on, Friday, January 20th, 2023
• Yun Zhong of "BTIG" Maintained at Strong Buy with Increased Target to $160 on, Thursday, December 22nd, 2022
• Colin Bristow of "UBS" Upgraded from Hold to Strong Buy and Increased Target to $158 on, Friday, December 16th, 2022

Contributing Sources

---